For years, labs have had variable success during audits (or during prior authorization), depending on how much original physician-side chart documentation must be procured by a lab.
Notably, MolDx published an article that a physician's order (often with ICD10 codes, etc) is an integral and valid part of the medical records as a whole. A59798. My blog here.
A recent court case revisits this. See the case online here, 36pp. See expert discussion by Jampol et al at Epstein Becker Green here.
###
Here is an AI assessment of the documents.
###
AI CORNER
###
The First Circuit’s OMNI v. MD Spine decision is important for labs because it supports a practical rule: a laboratory may generally rely on a physician’s test order as evidence of medical necessity, absent red flags or lab misconduct.
That matters in audits, where labs are often pressed to obtain underlying physician chart notes, not just orders. The case does not give blanket immunity, but it helps distinguish the lab’s billing responsibility from the physician’s underlying clinical judgment.
###
From the lab industry viewpoint, the First Circuit’s decision is important because it pushes back against an increasingly burdensome theory of audit and FCA exposure: that a laboratory may receive a facially valid physician order, run the ordered test, bill Medicare, and then later be told that the order itself was not enough—that the lab should also have procured and retained the physician’s underlying chart notes or other physician-owned documentation to prove medical necessity. In OMNI v. MD Spine, the court did not frame the issue as a record-request case in those exact words, but its reasoning strongly supports the more practical lab-side position: a lab generally may rely on the ordering physician’s requisition/order as evidence that the test was medically necessary, unless the lab had red flags or engaged in misconduct of its own.
The case as a whole arose from allegations that MD Labs billed Medicare for PCR UTI tests that OMNI said were more expensive and no better than ordinary urine culture, and therefore medically unnecessary. But the record developed an unusual twist: OMNI’s physician-owner had instructed staff to order PCR tests even when clinicians had asked for the older culture test, apparently to help build an FCA case. The First Circuit still focused on the key FCA question: did the lab knowingly submit false claims? It agreed with the district court that the answer was no. The court emphasized that scienter under the FCA turns on the lab’s subjective belief at the time of claim submission, not hindsight and not what someone later argues a reasonable person should have known.
For labs, the core holding is the crucial sentence: a laboratory can generally rely on a doctor’s order to show that the test is “reasonable and necessary.” The court treated the physician order as a kind of safe harbor starting point on medical necessity. Once the lab shows it had the doctor’s order, the burden shifts to the FCA claimant to rebut that reliance with evidence that the lab ignored warning signs or acted improperly.
- That is a major practical boundary line.
- It means the lab is not automatically transformed into the auditor of the physician’s full chart, differential diagnosis, and office note every time it receives a completed requisition.
That matters because the court repeatedly grounded its reasoning in the distinct role of the laboratory. The opinion says labs do not diagnose patients and do not decide what tests are medically necessary; they process tests ordered by licensed providers. The court openly worried that the opposite rule would force labs to second-guess physicians, delay testing while they re-audited orders, or even substitute cheaper services just to avoid FCA risk. From a lab operations standpoint, that is exactly the real-world issue: if every requisition is only provisional until the lab has chased down physician-owned progress notes, the lab becomes partly a records-collection company rather than a testing company.
On your specific point about medical record sufficiency, the opinion strongly implies that a properly completed test order/requisition is itself meaningful medical-record evidence, not an empty administrative shell. The court says the doctor’s determination of medical necessity is “inherent, if not explicitly stated, in the order for the test.” It also refers to the requisition form being “in-hand” and treats that order as the concrete basis for the lab’s reliance. In lab terms, that is very favorable language. It does not say the lab must routinely obtain the physician’s original chart note before the claim is defensible. Rather, it says the order itself ordinarily supports the lab’s reliance, absent red flags.
That does not mean the lab can be sloppy about documentation. The opinion and the EBG summary both preserve an independent lab duty to maintain proper records and compliance controls. The lab should retain the physician order, avoid changing the order without consent, ensure coding is appropriate, and document communications with providers. But that is a different proposition from saying the lab must always laboriously procure and warehouse the doctor’s underlying chart documentation as the only acceptable proof of necessity. The decision points toward a more balanced rule: retain the order, watch for red flags, escalate when something looks wrong.
The court was equally clear that the physician-order rule is not blanket immunity. A lab can still lose protection if it creates the problem itself. Examples given in the opinion and summary include misleading marketing, pressuring physicians, designing requisition forms that nudge or force medically unnecessary panels, adding services beyond what was ordered, or proceeding despite clear signs that the doctor did not understand what was being ordered. This is especially important for labs selling molecular panels or other high-complexity services. The protection comes from reliance on an independent physician’s order, not from hiding behind that order after the lab has manipulated the ordering process.
So the practical takeaway for audited labs is narrower and more useful than “orders are always enough.” It is this: a physician’s order is ordinarily sufficient to establish the lab’s good-faith basis to bill, but only so long as the lab has no meaningful reason to distrust it. The EBG summary lists examples of triggers for further inquiry: unusual volumes, abrupt ordering-pattern changes, inconsistent or contradictory requisitions, highly templated orders, or signs the provider misunderstood the test. Once those warning signs appear, passive reliance becomes less defensible, and the lab should seek clarification. That is where additional physician documentation may become important—not as a universal prerequisite, but as a response to red flags.
Viewed that way, the case is a welcome correction for the industry. Labs have long worried that Medicare contractors, UPICs, or FCA relators might collapse two different questions into one: first, whether the physician had adequate clinical justification to order the test; second, whether the lab knowingly submitted a false claim. The First Circuit keeps those concepts separate. A lab is not automatically liable just because someone later disputes the physician’s medical judgment. The lab’s own scienter still matters, and the presence of a physician order weighs heavily against scienter.
Put bluntly, from the lab side the case says: the lab is not the medical-necessity police. It may rely on the ordering physician’s order as a real and significant part of the medical record. As you note, MolDx has previously published guidance stating that a physician’s lab order can be viewed as an integral and satisfactory component of the medical record. I am not linking that here, per your instruction. The First Circuit’s reasoning is not identical to a MolDx article, but it is plainly congenial to that operational view of the world.
The Bottom Line
My bottom-line lab reading is this: OMNI v. MD Spine is a pro-lab decision on reliance, not a free pass on compliance. It supports the proposition that a complete physician order—with the ordered test and ordinary claim elements such as diagnosis coding where applicable—can ordinarily be enough for the lab to proceed and bill without first obtaining the physician’s entire underlying chart. But it also tells labs to keep their own house clean: no coercive forms, no stealth bundling, no altered orders, no careless coding, and no ignoring patterns that would make reliance unreasonable.
##
The Case as a Whole
As a whole, the case ended very well for the lab on the appealed medical-necessity issue. The First Circuit affirmed summary judgment for MD Labs, holding that OMNI had not produced enough evidence that the lab knowingly submitted false claims. In other words, even if one thought the PCR urine testing was expensive, aggressive, or debatably overused, the relator still failed on the key FCA element of scienter. The court said the lab could generally rely on the physician’s order and was not required to second-guess the doctor absent red flags or misconduct by the lab.
There was also an unusual factual twist that challenged OMNI: OMNI’s own physician-owner had instructed staff to order PCR tests even when clinicians had asked for BUC tests, apparently to help generate an FCA case. The court noted that nothing showed MD Labs knew about those internal tactics. So the lab was sitting there with physician requisitions in hand, while the relator later argued the tests should not have been ordered. That made the scienter theory especially weak.
At the district court level, MD Labs had sought summary judgment on several grounds, including that the tests were not false claims, that causation was broken by the physician’s own ordering conduct, and that the lab lacked scienter. The district court granted summary judgment based on the scienter ground alone, and the First Circuit affirmed on that basis. So the appellate court did not need to hold broadly that the PCR tests were always medically necessary, or that the testing model was ideal. It held instead that OMNI had not shown the lab knowingly submitted false claims. That is an important distinction, and probably the cleanest way to read the opinion.
So your instinct is right: the case does not read like a ringing judicial endorsement of lots of molecular urine testing as a general practice. It reads more like a decision that, whatever one thinks about that testing pattern, this relator did not prove FCA liability against this lab. The court was willing to say, in effect, “maybe the medicine is debatable, but that does not automatically make the lab" in the wrong in a FCA case.
There was also a broader procedural point: MD Labs had already settled other issues with the government and OMNI earlier in the case, and OMNI retained the right to pursue this remaining medical-necessity/FCA theory. That remaining theory is the one that failed. So the “whole case” did not end with total vindication on every historical issue ever raised; rather, the surviving appealed issue ended with a defense win for the lab.
My one-sentence bottom line: the lab won the appealed case because the court found insufficient evidence that it knowingly billed Medicare falsely, not because the court needed to fully bless the underlying molecular UTI-testing business.
###
Most of the clais were circa 2017 2018 2019 before the MolDx (and thus Noridian) crackdown on UTI molecular testing, which would have affected a Nevada-based lab billing Noridian.
###
MD Labs did not rely only on the “we had doctors’ orders” argument.** That was its **main legal shield** on scienter, but the record also shows it offered **substantive support that PCR/UTI testing was not outside the bounds of reasonable practice**.
Most notably, the First Circuit says MD Labs had **consulted an infectious disease doctor about the PCR tests**, and that doctor told the lab about the tests’ **importance in patient care**. The court used that fact when rejecting OMNI’s effort to portray the founders’ internal emails as showing awareness of falsity.
And on the **panel/bundling** issue, MD Labs went further still. The opinion says MD Labs offered an **expert infectious disease physician report** stating that the pathogens included in its panels **“are reasonable”** and **“within the range endorsed” by a peer-reviewed article**.
The court then noted that the plaintiff OMNI did **not** respond with record evidence showing the panel makeup was unnecessarily broad.
So the lab’s position was really a **two-track defense**:
**First**, legally, it said: *we received apparently valid physician requisitions and could generally rely on them.*
**Second**, factually, it said: *and in any event, this was not some crazy fringe testing model; we had infectious-disease input and expert support that the pathogens/panels were within a reasonable clinical range.*
That said, the court’s actual holding rested on **scienter**, not on a sweeping endorsement of molecular urine testing as best practice. The First Circuit specifically emphasized reliance on the physician orders and the lack of evidence that MD Labs should have doubted them. So the clinical “reasonableness” material helped the defense, but the decisive point was still that OMNI failed to prove the lab **knowingly** submitted false claims.
